{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Hypoxia inducible factor",
      "Mitochondria",
      "Oxidative phosphorylation",
      "Pyruvate dehydrogenase",
      "Pyruvate dehydrogenase kinase",
      "Warburg metabolism"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33974932",
  "DateCompleted": {
    "Year": "2021",
    "Month": "06",
    "Day": "28"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "06",
    "Day": "28"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "05",
        "Day": "08"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.lfs.2021.119597",
      "S0024-3205(21)00583-X"
    ],
    "Journal": {
      "ISSN": "1879-0631",
      "JournalIssue": {
        "Volume": "278",
        "PubDate": {
          "Year": "2021",
          "Month": "Aug",
          "Day": "01"
        }
      },
      "Title": "Life sciences",
      "ISOAbbreviation": "Life Sci"
    },
    "ArticleTitle": "Part-time cancers and role of melatonin in determining their metabolic phenotype.",
    "Pagination": {
      "StartPage": "119597",
      "MedlinePgn": "119597"
    },
    "Abstract": {
      "AbstractText": [
        "This brief review describes the association of the endogenous pineal melatonin rhythm with the metabolic flux of solid tumors, particularly breast cancer. It also summarizes new information on the potential mechanisms by which endogenously-produced or exogenously-administered melatonin impacts the metabolic phenotype of cancer cells. The evidence indicates that solid tumors may redirect their metabolic phenotype from the pathological Warburg-type metabolism during the day to the healthier mitochondrial oxidative phosphorylation on a nightly basis. Thus, they function as cancer cells only during the day and as healthier cells at night, that is, they are only part-time cancerous. This switch to oxidative phosphorylation at night causes cancer cells to exhibit a reduced tumor phenotype and less likely to rapidly proliferate or to become invasive or metastatic. Also discussed is the likelihood that some solid tumors are especially aggressive during the day and much less so at night due to the nocturnal rise in melatonin which determines their metabolic state. We further propose that when melatonin is used/tested in clinical trials, a specific treatment paradigm be used that is consistent with the temporal metabolic changes in tumor metabolism. Finally, it seems likely that the concurrent use of melatonin in combination with conventional chemotherapies also would improve cancer treatment outcomes."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021. Published by Elsevier Inc."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, TX 78229, USA. Electronic address: Reiter@uthscsa.edu."
          }
        ],
        "LastName": "Reiter",
        "ForeName": "Russel J",
        "Initials": "RJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, TX 78229, USA."
          }
        ],
        "LastName": "Sharma",
        "ForeName": "Ramaswamy",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Departamento de Morfologia y Biologia Celular, Facultad de Medicina, Oviedo, 33006, Spain."
          }
        ],
        "LastName": "Rodriguez",
        "ForeName": "Carmen",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Departamento de Morfologia y Biologia Celular, Facultad de Medicina, Oviedo, 33006, Spain."
          }
        ],
        "LastName": "Martin",
        "ForeName": "Vanesa",
        "Initials": "V"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centro de Investigacion Biomedica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara CP 45150, Mexico."
          }
        ],
        "LastName": "Rosales-Corral",
        "ForeName": "Sergio",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Faculdade de Medicina de Sao Jose do Rio Preto, Laboratorio de Investigacao Molecular do Cancer, Sao Jose Do Rio Preto, Sao Paulo 1508000, Brazil."
          }
        ],
        "LastName": "Zuccari",
        "ForeName": "Debora Aparecida Pires de Campos",
        "Initials": "DAPC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Departamento de Biologia Estrutural e Funcional, Instituto de Biociencias, Botucatu, Sao Poalo 18618-689, Brazil."
          }
        ],
        "LastName": "Chuffa",
        "ForeName": "Luiz Gustavo de Almeida",
        "Initials": "LGA"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Life Sci",
    "NlmUniqueID": "0375521",
    "ISSNLinking": "0024-3205"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antioxidants"
    },
    {
      "RegistryNumber": "JL5DK93RCL",
      "NameOfSubstance": "Melatonin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "metabolism",
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "metabolism",
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Antioxidants"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "metabolism",
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Melatonin"
    },
    {
      "QualifierName": [
        "drug effects",
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Mitochondria"
    },
    {
      "QualifierName": [
        "drug therapy",
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Oxidative Phosphorylation"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Warburg Effect, Oncologic"
    }
  ]
}